RCRajasree Chakraborty

Rajasree Chakraborty

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Rajasree Chakraborty has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The role of chromatin in retroviral preintegration complex function

    by Nicklas Sapp, Prem Prakash, Rajasree Chakraborty, Muthukumar Balasubramaniam, Chandravanu Dash


  • HIV-Associated Hypertension: Risks, Mechanisms, and Knowledge Gaps

    by Prem Prakash, Berwin Singh Swami Vetha, Rajasree Chakraborty, Tara-Yesomi Wenegieme, Sepiso K. Masenga, Gladson Muthian, Muthukumar Balasubramaniam, Celestine N. Wanjalla, Antentor O. Hinton, Annet Kirabo, et al.

    HIV type 1 (HIV-1) is the causative agent of AIDS. Since the start of the epidemic, HIV/AIDS has been responsible for ≈40 million deaths. Additionally, an estimated 39 million people are currently infected with the virus. HIV-1 primarily infects immune cells, such as CD 4+ (cluster of differentiation 4 + ) T lymphocytes (T cells), and as a consequence, the number of CD 4+ T cells progressively declines in people living with HIV. Within a span of ≈10 years, HIV-1 infection leads to the systemic failure of the immune system and progression to AIDS. Fortunately, potent antiviral therapy effectively controls HIV-1 infection and prevents AIDS-related deaths. The efficacy of the current antiviral therapy regimens has transformed the outcome of HIV/AIDS from a death sentence to a chronic disease with a prolonged lifespan of people living with HIV. However, antiviral therapy is not curative, is challenged by virus resistance, can be toxic, and, most importantly, requires lifelong adherence. Furthermore, the improved lifespan has resulted in an increased incidence of non-AIDS–related morbidities in people living with HIV including cardiovascular diseases, renal disease, liver disease, bone disease, cancer, and neurological conditions. In this review, we summarize the current state of knowledge of the cardiovascular comorbidities associated with HIV-1 infection, with a particular focus on hypertension. We also discuss the potential mechanisms known to drive HIV-1–associated hypertension and the knowledge gaps in our understanding of this comorbid condition. Finally, we suggest several directions of future research to better understand the factors, pathways, and mechanisms underlying HIV-1–associated hypertension in the post-antiviral therapy era.


  • Antiproliferative and Apoptotic Potential of Methotrexate Lipid Nanoparticles in A Murine Breast Cancer Model

    by Chaitali Surve, Ananya Banerjee, Anupriya S, Rajasree Chakraborty, Dhiraj Kumar, Ramesh Butti, Mahadeo Gorain, Sabyasachi Parida, Gopal C Kundu, Supriya Shidhaye, et al.

    Aim: To evaluate the efficacy of novel methotrexate-loaded nanoparticles (MTX-NPs) in vitro and in vivo in the treatment of breast cancer. Materials & methods: MTX-NPs were tested for cellular upta...